Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093755 | 0.93 | NAAA (0.40) | CA2CA9CA1ESR2ESR1 | |
| SCHEMBL3343263 | 0.84 | LSS (0.37) | CA2CA9KCNH2LSSCARM1 | |
| SCHEMBL20187448 | 0.83 | SPHK1 (0.42) | CA2CA9CA1KCNA5KCNH2 | |
| SCHEMBL4952656 | 0.82 | CA2 (0.58) | CA2CA9CA1CYP3A4 | |
| SCHEMBL9273240 | 0.79 | LSS (0.42) | SPHK1LSS | |
| SCHEMBL15771678 | 0.78 | CA2 (0.43) | CA2CA9CA1DAGLB | |
| SCHEMBL3342643 | 0.78 | GPR119 (0.57) | — | |
| SCHEMBL16727007 | 0.77 | CA1 (0.33) | CA2CA9CA1 | |
| SCHEMBL19845815 | 0.77 | CA2 (0.52) | CA2CA9CA1DAGLB | |
| SCHEMBL18185873 | 0.76 | PTPN1 (0.49) | CA2CA9NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11458149-B1 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2006-06-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | CA2 1738/4885CA9 864/4885CA1 2177/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | CA2 1738/4885CA9 864/4885CA1 2177/4885 |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | CA2 413/4885CA9 503/4885CA1 3096/4885 |
| US-11458149-B1 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | CA2 1738/4885CA9 864/4885CA1 2177/4885 |
| US-20060142209-A1 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | SLC5A2, SLC5A1, UGGT1 | CA2 1252/4885CA9 1329/4885CA1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.